Ikarian Capital »

Lyell Immunopharma shares owned by Ikarian Capital

Quarter-by-quarter ownership of Lyell Immunopharma (LYEL) shares owned by Ikarian Capital from 13F filings

Historical chart of Ikarian Capital investment in Lyell Immunopharma

Tip: Access up to 7 years of quarterly data

All positions including Lyell Immunopharma held by Ikarian Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lyell Immunopharma by Ikarian Capital

Quarter filed Position value Share count Share price at filing
2025-09-30 $711k 44k 16.24
2025-06-30 $387k 44k 8.84

More positions owned by Ikarian Capital

United Therapeutics Corporation Put Option (UTHR)
Spdr Series Trust S&p Biotech Put Option (XBI)
Genmab A/s Sponsored Ads (GMAB)
Bristol Myers Squibb Put Option (BMY)
Abivax Sa Sponsored Ads (ABVX)
Uniqure Nv Call Call Option
Insmed Com Par $.01 (INSM)
Ptc Therapeutics I (PTCT)
Ionis Pharmaceuticals (IONS)
Cidara Therapeutics Com New (CDTX)
Scholar Rock Hldg Corp Put Option (SRRK)
Rapt Therapeutics Com New (RAPT)
Maze Therapeatics (MAZE)
Soleno Therapeutics (SLNO)
Cytokinetics Com New (CYTK)

View all positions for Ikarian Capital

Top funds holding Lyell Immunopharma

Arch Venture Corp
MWG Management
Foresite Capital Management IV
Vanguard Group
Orland Properties
Almitas Capital
Foresite Capital Management V
venBio Partners
Citadel Advisors
Alphabet
BlackRock
Sc China Holding
Geode Capital Management
Millennium Management
Rbf Capital

View all funds holding Lyell Immunopharma